This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
XOMA Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
XOMA's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in XOMA.
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 52.38% and -75.78%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
XOMA's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in XOMA.
Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XOMA (XOMA) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
XOMA (XOMA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Xoma (XOMA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xoma (XOMA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will XOMA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in XOMA.
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Will XOMA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor XOMA.
Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Firm's First Profit Can Mean Big Returns for Investors
by Benjamin Rains
We are already roughly halfway through second-quarter 2019 earnings season. This means now could be a great time to look at a 'First Profit' stock screen.
Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.
Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.